Trials / Completed
CompletedNCT06090721
DMT310-009 Topical in the Treatment of Acne Vulgaris
A PHASE 3 STUDY OF TOLERABILITY, SAFETY, AND EFFICACY, OF DMT310 IN PATIENTS WITH ACNE VULGARIS
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 520 (actual)
- Sponsor
- Dermata Therapeutics · Industry
- Sex
- All
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DMT310 | Topical Powder |
| DRUG | Placebo | Placebo Topical Powder |
Timeline
- Start date
- 2023-12-08
- Primary completion
- 2025-03-31
- Completion
- 2025-04-30
- First posted
- 2023-10-19
- Last updated
- 2025-08-22
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06090721. Inclusion in this directory is not an endorsement.